Cohera Medical, Inc. Receives Approval To Begin Human Clinical Trials of TissuGlu(R) in Europe

Friday, October 23, 2009 General News
Email Print This Page Comment
Font : A-A+

PITTSBURGH, Oct. 23 -- Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials

of its lead product TissuGluŽ in Germany. Receipt of the approval allows Cohera Medical to proceed with patient recruitment and initiation of an investigational study of the company's novel internal surgical adhesive
being developed for its first intended use to adhere surgical tissues together in large flap surgeries.

The feasibility study will investigate the safety and preliminary effectiveness of TissuGluŽ and its effect on wound drainage and associated complications in abdominoplasty (tummytuck) surgeries.  The study will be conducted at three sites near Bonn, Frankfurt, and Freiburg in Germany and will enroll 40 patients.  Patient recruitment is expected to begin in November this year.

Currently, patients who undergo abdominoplasty require the insertion of drains to remove fluids that accumulate under the skin at the surgical site.  In some cases, drainage is inadequate and excessive fluid accumulation (called seroma formation) often requires an additional procedure to remove it.  TissuGlu is designed to adhere the tissue flaps created during the procedure, thereby reducing fluid accumulation and ultimately reduce or eliminate the need for surgical drains and reduce the risk of related complications.  Patients are expected to experience a faster and more comfortable recovery with the use of TissuGlu.

"This trial will be our first study of TissuGlu in patients and the trial's approval validates the biocompatibility and pre-clinical profile of TissuGlu," said Chad Coberly, JD, vice president of clinical, regulatory and legal affairs of Cohera.  "Initiation of this study will allow the company to move closer to a regulatory approval application in Europe for the CE Mark and application for a larger U.S. based trial.  

Patrick Daly, president and chief executive officer of Cohera Medical added, "This approval represents a major milestone for our internal adhesive technology and for Cohera.  Our company is focused on progressing TissuGlu to the next stage of development in the commercialization process.  This unique product will ultimately help surgeons address a critical need and improve patient care."

About Cohera Medical

Cohera Medical, Inc. is a Pittsburgh, PA based company that is developing a revolutionary line of surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is an adhesive for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation, small bone fixation, and other plastic surgery indications, which will fill similar market needs in both plastic, orthopedics, and general surgery. For more information, visit TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.

SOURCE Cohera Medical, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store